Fig. 3: ctDNA monitoring. | npj Breast Cancer

Fig. 3: ctDNA monitoring.

From: Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy

Fig. 3

a ctDNA kinetics in patients with ctDNA detected at baseline until discontinuation or last follow-up. Failed samples are not shown. b Early ctDNA kinetics did not predict TTF (case vignettes). c Waterfall plot showcasing eVAF decrease from baseline and RECIST v1.1 target lesion change at best response. Dashed lines denote +20% and −30% thresholds for progressive disease and partial response as per RECIST v1.1. CR complete response, NA not applicable, PD progressive disease, PR partial response, SD stable disease.

Back to article page